Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?

Bone Marrow Transplantation volume 52, pages 352–356 (2017)Cite this article

Subjects

Abstract

Diagnosis and management of hematopoietic cell transplant-associated thrombotic microangiopathy (TA-TMA) are very complex and controversial, given multiple ongoing issues and comorbidities in sick transplant recipients. Complement activation via classic and alternative pathways is emerging as a potential pathogenetic mechanism in the development of TA-TMA. Complement-centric diagnostic strategy using functional and genetic tests may possibly support diagnosis, enhance molecular understanding and direct drug development. Complement blockade using eculizumab has shown some promising rates of hematologic responses, however, survival may still be poor. Early discontinuation of calcineurin inhibitor where feasible, use of eculizumab, aggressive infection prophylaxis, close monitoring and early treatment of potential complications including GvHD and organ failure may improve outcomes. A number of complement inhibitors are in the development and may change treatment paradigm. Future studies are important to better understand TA-TMA as a disease process and may aim to confirm the role of complement activation in TA-TMA, enhance diagnostic strategy, determine therapeutic approaches and strategies to reduce the risk of other complications particularly infection and GvHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Elsallabi O, Bhatt VR, Dhakal P, Foster KW, Tendulkar KK . Hematopoietic stem cell transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 2016; 22: 12–20.

    Article  CAS  PubMed  Google Scholar 

  2. Batts ED, Lazarus HM . Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant 2007; 40: 709–719.

    Article  CAS  PubMed  Google Scholar 

  3. Hingorani S . Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment. J Am Soc Nephrol 2006; 17: 1995–2005.

    Article  PubMed  Google Scholar 

  4. Laskin BL, Goebel J, Davies SM, Jodele S . Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 2011; 118: 1452–1462.

    Article  CAS  PubMed  Google Scholar 

  5. Cho BS, Yahng SA, Lee SE, Eom KS, Kim YJ, Kim HJ et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation 2010; 90: 918–926.

    Article  CAS  PubMed  Google Scholar 

  6. Daly AS, Xenocostas A, Lipton JH . Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant 2002; 30: 709–715.

    Article  CAS  PubMed  Google Scholar 

  7. Martinez MT, Bucher C, Stussi G, Heim D, Buser A, Tsakiris DA et al. Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 2005; 36: 993–1000.

    Article  CAS  PubMed  Google Scholar 

  8. Ye Y, Zheng W, Wang J, Hu Y, Luo Y, Tan Y et al. Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study. Hematol Oncol 2016 (e-pub ahead of print 1 June 2016; doi:10.1002/hon.2310).

    Article  PubMed  Google Scholar 

  9. Jodele S, Hirsch R, Laskin B, Davies S, Witte D, Chima R . Pulmonary arterial hypertension in pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 2013; 19: 202–207.

    Article  PubMed  Google Scholar 

  10. George JN . How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010; 116: 4060–4069.

    Article  CAS  PubMed  Google Scholar 

  11. George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB . Thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004; 44: 294–304.

    Article  PubMed  Google Scholar 

  12. Choi C, Schmaier A, Snell M, Lazarus H . Thrombotic microangiopathy in haematopoietic stem cell transplantation. Drugs 2009; 69: 183–198.

    Article  CAS  PubMed  Google Scholar 

  13. Hingorani S . Renal complications of hematopoietic-cell transplantation. N Engl J Med 2016; 374: 2256–2267.

    Article  PubMed  Google Scholar 

  14. Verbiest A, Pirenne J, Dierickx D . De novo thrombotic microangiopathy after non-renal solid organ transplantation. Blood Rev 2014; 28: 269–279.

    Article  PubMed  Google Scholar 

  15. Chapin J, Shore T, Forsberg P, Desman G, Van Besien K, Laurence J . Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol 2014; 12: 565–573.

    PubMed  Google Scholar 

  16. Worel N, Greinix HT, Leitner G, Mitterbauer M, Rabitsch W, Rosenmayr A et al. ABO-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: close association with transplant-associated microangiopathy. Transfus Apher Sci 2007; 36: 297–304.

    Article  PubMed  Google Scholar 

  17. Ferrara JL, Levine JE, Reddy P, Holler E . Graft-versus-host disease. Lancet 2009; 373: 1550–1561.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Furlong T, Storb R, Anasetti C, Appelbaum F, Deeg H, Doney K et al. Clinical outcome after conversion to FK 506(tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant 2000; 26: 985–991.

    Article  CAS  PubMed  Google Scholar 

  19. Boyer NL, Niven A, Edelman J . Tacrolimus-associated thrombotic microangiopathy in a lung transplant recipient. BMJ Case Rep 2013; bcr2012007351.

    Google Scholar 

  20. Chhajed PN, Tamm M, Glanville AR . Role of flexible bronchoscopy in lung transplantation. Semin Respir Crit Care Med 2004; 25: 413–423.

    Article  PubMed  Google Scholar 

  21. Fishman JA . Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601–2614.

    Article  CAS  PubMed  Google Scholar 

  22. Legro IR, Shah S, Kaza V . Tacrolimus induced hemolytic uremic syndrome in a lung transplant patient. Am J Respir Crit Care Med 2010; 181: A5834.

  23. Humar A, Jessurun J, Sharp HL, Gruessner RW . Hemolytic uremic syndrome in small-bowel transplant recipients: the first two case reports. Transpl Int 1999; 12: 387–390.

    Article  CAS  PubMed  Google Scholar 

  24. Paramesh AS, Grosskreutz C, Florman SS, Gondolesi GE, Sharma S, Kaufman SS et al. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. Transplantation 2004; 77: 129–131.

    Article  PubMed  Google Scholar 

  25. Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 551–557.

    Article  CAS  PubMed  Google Scholar 

  26. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571–575.

    Article  PubMed  Google Scholar 

  27. Wolff D, Wilhelm S, Hahn J, Gentilini C, Hilgendorf I, Steiner B et al. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. Bone Marrow Transplant 2006; 38: 445–451.

    Article  CAS  PubMed  Google Scholar 

  28. George JN, Terrell DR, Vesely SK, Kremer Hovinga JA, Lammle B . Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. Presse Med 2012; 41: e177–e188.

    Article  PubMed  Google Scholar 

  29. Iacopino P, Pucci G, Arcese W, Bosi A, Falda M, Locatelli F et al. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Bone Marrow Transplant 1999; 24: 47–51.

    Article  CAS  PubMed  Google Scholar 

  30. Jodele S, Laskin BL, Goebel J, Khoury JC, Pinkard SL, Carey PM et al. Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy? Transfusion 2013; 53: 661–667.

    Article  CAS  PubMed  Google Scholar 

  31. Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 2014; 40: 444–464.

    Article  PubMed  Google Scholar 

  32. Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen EP, Drobyski WR et al. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 1995; 16: 271–275.

    CAS  PubMed  Google Scholar 

  33. Au WY, Ma ES, Lee TL, Ha SY, Fung AT, Lie AK et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol 2007; 137: 475–478.

    Article  CAS  PubMed  Google Scholar 

  34. Carella AM, D'Arena G, Greco MM, Nobile M, Cascavilla N . Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura. Bone Marrow Transplant 2008; 41: 1063–1065.

    Article  CAS  PubMed  Google Scholar 

  35. Marr H, McDonald EJ, Merriman E, Smith M, Mangos H, Stoddart C et al. Successful treatment of transplant-associated microangiopathy with rituximab. N Z Med J 2009; 122: 72–74.

    PubMed  Google Scholar 

  36. Ostronoff M, Ostronoff F, Calixto R, Florencio R, Florencio M, Domingues MC et al. Life-threatening hemolytic-uremic syndrome treated with rituximab in an allogeneic bone marrow transplant recipient. Bone Marrow Transplant 2007; 39: 649–651.

    Article  CAS  PubMed  Google Scholar 

  37. Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation–associated thrombotic microangiopathy. Biol Blood Marrow Transplant 2014; 20: 518–525.

    Article  CAS  PubMed  Google Scholar 

  38. Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563–570.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753–760.

    Article  CAS  PubMed  Google Scholar 

  40. Laskin BL, Maisel J, Goebel J, Yin HJ, Luo G, Khoury JC et al. Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation 2013; 96: 217–223.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013; 122: 2003–2007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 2015; 29: 191–204.

    Article  PubMed  Google Scholar 

  43. Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014; 124: 645–653.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014; 124: 1715–1726.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Afshar-Kharghan V . COMPLEMENTing the diagnosis of aHUS. Blood 2014; 124: 1699–1700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Cohen D, Colvin RB, Daha MR, Drachenberg CB, Haas M, Nickeleit V et al. Pros and cons for C4d as a biomarker. Kidney Int 2012; 81: 628–639.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 2016; 127: 989–996.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Kim SS, Patel M, Yum K, Keyzner A . Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options. Transfusion 2014; 55: 452–458.

    Article  PubMed  Google Scholar 

  49. Jodele S, Dandoy CE, Myers KC, El-Bietar J, Nelson A, Wallace G et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transfus Apher Sci 2016; 54: 181–190.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Dhakal P, Giri S, Pathak R, Bhatt VR . Eculizumab in transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 2015 (e-pub ahead of print 9 August 2016; doi:10.1177/1076029615599439).

    Article  Google Scholar 

  51. de Fontbrune FS, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S et al. Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation 2015; 99: 1953–1959.

    Article  CAS  PubMed  Google Scholar 

  52. Vasu S, Wu H, Satoskar A, Puto M, Roddy J, Blum W et al. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant 2016; 51: 1241–1244.

    Article  CAS  PubMed  Google Scholar 

  53. Fernández C, Lario A, Forés R, Cabrera R . Eculizumab treatment in a patient with hematopoietic stem cell transplantation-associated thrombotic microangiopathy and steroid-refractory acute graft versus host disease. Hematol Rep 2015; 7: 6107.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Morales E, Rabasco C, Gutierrez E, Praga M . A case of thrombotic micro‐angiopathy after heart transplantation successfully treated with eculizumab. Transpl Int 2015; 28: 878–880.

    Article  PubMed  Google Scholar 

  55. Sevindik ÖG, Alacacıoğlu İ, Katgı A, Solmaz ŞM, Acar C, Pişkin Ö et al. Renal and neurological response with eculizumab in a patient with transplant associated thrombotic microangiopathy after allogeneic hematopoietic progenitor cell transplantation. Case Rep Hematol 2015; 2015: 425410.

    PubMed  PubMed Central  Google Scholar 

  56. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233–1243.

    Article  CAS  PubMed  Google Scholar 

  57. Jodele S, Dandoy CE, Danziger-Isakov L, Myers KC, El-Bietar J, Nelson A et al. Terminal complement blockade after hematopoietic stem cell transplantation is safe without meningococcal vaccination. Biol Blood Marrow Transplant 2016; 22: 1337–1340.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Struijk GH, Bouts AHM, Rijkers GT, Kuin EAC, ten Berge IJM, Bemelman FJ . Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant 2013; 13: 819–820.

    Article  CAS  PubMed  Google Scholar 

  59. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C et al. Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome. N Engl J Med 2013; 368: 2169–2181.

    Article  CAS  PubMed  Google Scholar 

  60. Gavriilaki E, Thanassi JA, Yang G, Yuan X, Huang M, Brodsky RA . Small molecule factor D inhibitors block complement activation in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Blood 2015; 126: 275.

    Google Scholar 

  61. Keizer MP, Pouw RB, Kamp AM, Patiwael S, Marsman G, Hart MH et al. TFPI inhibits lectin pathway of complement activation by direct interaction with MASP-2. Eur J Immunol 2015; 45: 544–550.

    Article  CAS  PubMed  Google Scholar 

  62. Risitano AM, Ricklin D, Huang Y, Reis ES, Chen H, Ricci P et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014; 123: 2094–2101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Shi J, Rose EL, Singh A, Hussain S, Stagliano NE, Parry GC et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 2014; 123: 4015–4022.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

VR Bhatt is supported by the 2016–2017 Physician-Scientist Training Program Grant from the College of Medicine, University of Nebraska Medical Center. We extend our gratitude to Dr James N George, MD, University of Oklahoma Health Sciences Center, for kindly reviewing this article and providing useful insight.

Author information

Authors and Affiliations

  1. Department of Medicine, Michigan State University, East Lansing, MI, USA

    P Dhakal

  2. Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE, USA

    V R Bhatt

Authors
  1. P Dhakal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V R Bhatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Dhakal.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhakal, P., Bhatt, V. Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?. Bone Marrow Transplant 52, 352–356 (2017). https://doi.org/10.1038/bmt.2016.253

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.253

This article is cited by

Search

Advanced search

Quick links